Remission's not the same as being healthy.
Modern medicines can control inflammation and put patients into remission, but chronic inflammatory diseases often require persistent treatment to maintain that control.
Patients may face ongoing therapeutic burden, side effects, safety considerations and the continuing possibility of developing disease complications and comorbidities.
For patients, the goal isn't simply another period without symptoms. They want their health back and to live their lives without constantly managing their disease.
BRIDGE: A New Therapeutic Paradigm
EFFICACY ACROSS ORGAN SYSTEMS
One Intervention. Organic production of multiple bioactives. Activation of multiple therapeutic pathways associated with tissue healing and applicable to a spectrum of diseases. Human pilot study demonstrating proof-of-mechanism de-risking clinical development.
Exceptional Safety Profile for Long-term Use
An exceptional safety and delivery profile suitable for long-term treatment on its own, or as an adjunct therapy (after all, it's a patented drinking water formulation). Formulation is compatible with regulations for bottled drinking water.
Mechanism-Driven & Predictive Biomarkers
Functional biomarkers to identify responders before they are treated, with potential expansion across diseases and comorbidities. Opportunity for predictive intervention during clinical development, decreasing costs, improving time to market and ensuring patients receive the treatment that's best for them.
The BRIDGE Platform: Going Beyond Symptom Management
WHAT is BRIDGE?
THE BRIDGE HEALTH IMPACT
HOW BRIDGE WORKS
BRIDGE: Bioengineering Resilience to Inflammatory Disease through Gut Ecology
The gut microbiome is a key contributor to the pathogenesis of chronic diseases affecting the gut, skin, pancreas, lungs, immune and nervous systems. In the colon, microbial fermentation accumulates bioactive molecules (including short-chain fatty acids and hydr
BRIDGE: Bioengineering Resilience to Inflammatory Disease through Gut Ecology
The gut microbiome is a key contributor to the pathogenesis of chronic diseases affecting the gut, skin, pancreas, lungs, immune and nervous systems. In the colon, microbial fermentation accumulates bioactive molecules (including short-chain fatty acids and hydrogen sulfide) whose production is disrupted in chronic disease.
We asked: "How can we restore the function of the gut microbiome in chronic disease patients to re-establish accumulation of these beneficial molecules?"
HOW BRIDGE WORKS
THE BRIDGE HEALTH IMPACT
HOW BRIDGE WORKS
The gut microbiome is an ecosystem, much like a fish tank. Imagine taking fish from the ocean and placing them in an aquarium filled with tap water. The fish might survive, but the environment is no longer right for them to function normally.
Something similar happens in chronic disease: the microbes are still there, but the gut environm
The gut microbiome is an ecosystem, much like a fish tank. Imagine taking fish from the ocean and placing them in an aquarium filled with tap water. The fish might survive, but the environment is no longer right for them to function normally.
Something similar happens in chronic disease: the microbes are still there, but the gut environment may no longer support the metabolic functions we need them to perform.
So we developed BRIDGE: a patent-protected drinking water formulation designed to restore the gut environment and stimulate the microbiome to produce beneficial bioactive molecules at therapeutic levels.
THE BRIDGE HEALTH IMPACT
THE BRIDGE HEALTH IMPACT
THE BRIDGE HEALTH IMPACT
We have evaluated BRIDGE across three levels of evidence. In vitro, we demonstrated that BRIDGE significantly increases gut microbiome-dependent production of butyrate and hydrogen sulfide. BRIDGE restored fiber-dependent bioactive accumulation in microbiomes from individuals who do not produce these bioactives. In preclinical models,
We have evaluated BRIDGE across three levels of evidence. In vitro, we demonstrated that BRIDGE significantly increases gut microbiome-dependent production of butyrate and hydrogen sulfide. BRIDGE restored fiber-dependent bioactive accumulation in microbiomes from individuals who do not produce these bioactives. In preclinical models, BRIDGE significantly improved survival following a lethal respiratory viral infection and protected lung tissue from inflammatory damage, with efficacy comparable to a pharmaceutical antiviral treatment group. Most importantly, BRIDGE has shown activity in humans. In an initial human pilot, we observed significant improvements in glucose control and systemic oxygenation.
Together, these findings support the potential of BRIDGE to prevent tissue damage, improve physiological resilience, and ultimately help patients restore their health.
AQABELA Pipeline
- PRISTINE SAFETY PROFILE
- Compatible with most therapeutics and potential use as adjunct therapy.
- Candidate Predictive Biomarkers
- Potential for simultaneous therapeutic support of common comorbidities like diabetes.
What if your next generation of medicines restored health?
A New Approach to Respiratory Viral Infection
A New Approach to Respiratory Viral Infection
A New Approach to Respiratory Viral Infection
Current antiviral strategies typically target specific viruses. BRIDGE takes a different approach by targeting the host biology that protects and repairs tissue during infection.
BRIDGE offers the potential to:
- Target a novel MOA — supporting natural host pathways involved in tissue protection and repair rather than directly targeting the v
Current antiviral strategies typically target specific viruses. BRIDGE takes a different approach by targeting the host biology that protects and repairs tissue during infection.
BRIDGE offers the potential to:
- Target a novel MOA — supporting natural host pathways involved in tissue protection and repair rather than directly targeting the virus. This approach can prevent antimicrobial resistance as well.
- Work across multiple viruses — providing a potentially broad approach to respiratory viral infections rather than being limited to a single pathogen.
- Support high-risk patients with comorbidities like diabetes.
- Offers a strong safety rationale using an oral formulation designed with long-term use and combination with existing therapies in mind.
- BRIDGE protected lung tissue and improve survival in a preclinical model of lethal influenza infection.
The next step
Aqabela is now advancing BRIDGE toward completion of the IND-enabling development package, with the goal of progressing to clinical testing.
Click RESPIRATORY below to contact us.
Exploring BRIDGE across chronic diseases
A New Approach to Respiratory Viral Infection
A New Approach to Respiratory Viral Infection
BRIDGE is designed to restore natural biological signals involved in inflammation, tissue repair and systemic physiology. This creates an opportunity to explore its potential beyond respiratory disease, across conditions where disrupted repair and chronic inflammation contribute to disease progression.
Aqabela is seeking pharmaceutical pa
BRIDGE is designed to restore natural biological signals involved in inflammation, tissue repair and systemic physiology. This creates an opportunity to explore its potential beyond respiratory disease, across conditions where disrupted repair and chronic inflammation contribute to disease progression.
Aqabela is seeking pharmaceutical partners to co-develop focused preclinical pilot studies in:
- Autoimmune disease — including IBD, where restoring tissue repair and inflammatory resolution may complement existing immune-targeted therapies.
- Inflammatory disease — testing whether BRIDGE can shift chronic inflammation toward productive tissue repair and reduce pathological remodeling.
- Metabolic disease — exploring its potential to influence systemic metabolic pathways and improve physiological resilience.
- Neurodegenerative disease — investigating whether restoration of gut-derived biological signals can influence pathways relevant to neuroinflammation and tissue homeostasis.
A low-risk path to explore new indications
Rather than committing immediately to a large development program, Aqabela proposes targeted, hypothesis-driven pilot studies designed to establish biological activity, define mechanism-linked biomarkers and identify the indications where BRIDGE has the greatest therapeutic potential.
We welcome pharmaceutical partners with a disease area, model or therapeutic hypothesis they would like to explore with BRIDGE.
Click CHRONIC DISEASE EXPLORATION below to contact us.
Living Agelessly
A New Approach to Respiratory Viral Infection
Living Agelessly
Aqabela is interested in partnering with consumer health and food companies to bring products with meaningful, science-backed health benefits to consumers.
Our technology can be incorporated into beverages, creating opportunities to develop products that do more than hydrate, they can support health and help people stay well.
We are particu
Aqabela is interested in partnering with consumer health and food companies to bring products with meaningful, science-backed health benefits to consumers.
Our technology can be incorporated into beverages, creating opportunities to develop products that do more than hydrate, they can support health and help people stay well.
We are particularly interested in partners looking to develop products targeting areas such as:
- Gut health
- Immune health
- Metabolic health
- Healthy ageing/Longevity
- Performance and recovery
Our ideal partner wants to combine consumer-friendly products with credible science and substantiated health claims, giving consumers greater confidence in the choices they make every day. We can help you do that. In fact, we've already identified hidden healthy properties in a select group of CPG food products.
Click HEALTHY BEVERAGES below to find out more about consumer applications of BRIDGE or visit the Website Menu for Full Food Value information.
Patents Available for Licencing
Aqabela have a portfolio of intellectual property applicable to the pharmaceutical, consumer health and CPG food industries.
PCT application
WO 2025/229356 A1
ORAL HYDRATION SOLUTION
GB2641209 (Pending UK)
Other countries to follow
Provisional Patents
GB2518224.7 Composition for fibre digestion and short chain fatty acid production
GB2518227.0 Composition for use in the production of hydrogen sulphide
GB2518231.2 A composition for aiding digestion of lactate
Trade Secrets
Aqabela have identified natural mineral water sources with demonstrated health properties supporting immunity, metabolic health and human performance. These are undervalued assets and acquisition targets.